The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis! The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous…
Continue Reading
With the right intentions, you can use your mind as a tool to achieve amazing things. You know how sometimes one rotten thing can ruin an otherwise wonderful day? What if you could stop that from happening, and stand up to the negativity that tries to interrupt your day? With mindfulness, you can. As a…
Continue Reading
In January 2021, we identified a need to address TMA’s occupancy and our desire to be the best stewards of the organization’s resources. In doing so, we found the Headquarters office in Alexandria, Virginia to be neither cost effective, or conducive to team collaboration in the way it was laid out. We set out on…
Continue Reading
Are you an adult (18 years old or older) diagnosed with dermatomyositis (DM)? Modus Outcomes, a patient-centered outcomes research organization, is conducting 60-minute phone interviews with patients with DM to ask about their experience of DM. They can schedule the interview when it is convenient for you. They will ask you questions about your DM…
Continue Reading
We know you have many talents, and we invite you to use them to help us improve the lives of myositis patients everywhere. Whether you have an eye for detail or are a natural leader, we have a job for you! Please let us know how you would like to help.
Continue Reading